Canada may get twice-yearly HIV prevention shot by 2026

economictimes.indiatimes.com

A groundbreaking HIV prevention injection requiring only two doses per year could be available in Canada by mid-2026, offering a significant advancement in HIV prevention. The drug, lenacapavir, already approved in Canada for treatment, is under review for prevention after US FDA approval. Clinical trials demonstrated near-total effectiveness, with zero new infections in a study of high-risk women in Africa. Developed by Gilead Sciences, the drug's high cost raises concerns about accessibility, despite potential long-term cost-effectiveness. It will be administered by healthcare providers if approved.


With a significance score of 5.5, this news ranks in the top 0.6% of today's 26593 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: